OTCMKTS:CTYX

Curative Biotechnology Competitors

$0.12

-0.02 (-14.13 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.12

Now: $0.12▼

$0.15

50-Day Range

$0.15

MA: $0.16▼

$0.19

52-Week Range

$0.00

Now: $0.12▼

$0.22

Volume3.62 million shs

Average Volume3.04 million shs

Market Capitalization$47.20 million

P/E RatioN/A

Dividend YieldN/A

Beta-31.94

Curative Biotechnology (OTCMKTS:CTYX) Vs. CLBS, BXRX, CCEL, GRNV, EMMA, and PFHOD

Should you be buying CTYX stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to Curative Biotechnology, including Caladrius Biosciences (CLBS), Baudax Bio (BXRX), Cryo-Cell International (CCEL), GreenVision Acquisition (GRNV), Emmaus Life Sciences (EMMA), and Pacific Health Care Organization (PFHOD).

Curative Biotechnology vs. Caladrius Biosciences Stock

Caladrius Biosciences (NASDAQ:CLBS) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Institutional and Insider Ownership

9.0% of Caladrius Biosciences shares are owned by institutional investors. 10.3% of Caladrius Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Caladrius Biosciences has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, indicating that its stock price is 3,294% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Caladrius Biosciences and Curative Biotechnology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caladrius Biosciences	0	1	3	0	2.75
Curative Biotechnology	0	0	0	0	N/A

Caladrius Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 553.59%. Given Caladrius Biosciences' higher probable upside, research analysts clearly believe Caladrius Biosciences is more favorable than Curative Biotechnology.

Profitability

This table compares Caladrius Biosciences and Curative Biotechnology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caladrius Biosciences	N/A	-68.33%	-57.61%
Curative Biotechnology	N/A	N/A	N/A

Earnings and Valuation

This table compares Caladrius Biosciences and Curative Biotechnology's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caladrius Biosciences	N/A	N/A	$-19,360,000.00	($1.88)	-0.81
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A

Summary

Caladrius Biosciences beats Curative Biotechnology on 5 of the 7 factors compared between the two stocks.

Curative Biotechnology vs. Baudax Bio Stock

Baudax Bio (NASDAQ:BXRX) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Insider & Institutional Ownership

7.9% of Baudax Bio shares are owned by institutional investors. 13.1% of Baudax Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Baudax Bio and Curative Biotechnology's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baudax Bio	N/A	N/A	$-32,560,000.00	($3.48)	-0.31
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A

Volatility & Risk

Baudax Bio has a beta of 2.56, suggesting that its share price is 156% more volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, suggesting that its share price is 3,294% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Baudax Bio and Curative Biotechnology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baudax Bio	0	0	2	0	3.00
Curative Biotechnology	0	0	0	0	N/A

Baudax Bio presently has a consensus target price of $13.50, suggesting a potential upside of 1,161.68%. Given Baudax Bio's higher possible upside, research analysts clearly believe Baudax Bio is more favorable than Curative Biotechnology.

Profitability

This table compares Baudax Bio and Curative Biotechnology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Baudax Bio	N/A	N/A	N/A
Curative Biotechnology	N/A	N/A	N/A

Summary

Baudax Bio beats Curative Biotechnology on 5 of the 5 factors compared between the two stocks.

Curative Biotechnology vs. Cryo-Cell International Stock

Curative Biotechnology (OTCMKTS:CTYX) and Cryo-Cell International (OTCMKTS:CCEL) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Curative Biotechnology and Cryo-Cell International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curative Biotechnology	0	0	0	0	N/A
Cryo-Cell International	0	0	0	0	N/A

Institutional & Insider Ownership

1.0% of Cryo-Cell International shares are owned by institutional investors. 53.8% of Cryo-Cell International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Curative Biotechnology and Cryo-Cell International's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curative Biotechnology	N/A	N/A	N/A
Cryo-Cell International	10.39%	-58.74%	7.30%

Volatility and Risk

Curative Biotechnology has a beta of -31.94, meaning that its share price is 3,294% less volatile than the S&P 500. Comparatively, Cryo-Cell International has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Valuation & Earnings

This table compares Curative Biotechnology and Cryo-Cell International's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
Cryo-Cell International	$31.80 million	2.35	$2.29 million	N/A	N/A

Cryo-Cell International has higher revenue and earnings than Curative Biotechnology.

Summary

Cryo-Cell International beats Curative Biotechnology on 6 of the 7 factors compared between the two stocks.

Curative Biotechnology vs. GreenVision Acquisition Stock

Curative Biotechnology (OTCMKTS:CTYX) and GreenVision Acquisition (NASDAQ:GRNV) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares Curative Biotechnology and GreenVision Acquisition's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curative Biotechnology	N/A	N/A	N/A
GreenVision Acquisition	N/A	N/A	N/A

Valuation and Earnings

This table compares Curative Biotechnology and GreenVision Acquisition's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A

Insider and Institutional Ownership

67.7% of GreenVision Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Curative Biotechnology and GreenVision Acquisition, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curative Biotechnology	0	0	0	0	N/A
GreenVision Acquisition	0	0	0	0	N/A

Summary

GreenVision Acquisition beats Curative Biotechnology on 1 of the 1 factors compared between the two stocks.

Curative Biotechnology vs. Emmaus Life Sciences Stock

Emmaus Life Sciences (OTCMKTS:EMMA) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Emmaus Life Sciences and Curative Biotechnology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emmaus Life Sciences	0	0	0	0	N/A
Curative Biotechnology	0	0	0	0	N/A

Valuation & Earnings

This table compares Emmaus Life Sciences and Curative Biotechnology's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emmaus Life Sciences	$1.32 million	48.24	$-2,370,000.00	N/A	N/A
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A

Curative Biotechnology has lower revenue, but higher earnings than Emmaus Life Sciences.

Insider and Institutional Ownership

0.1% of Emmaus Life Sciences shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Emmaus Life Sciences has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, indicating that its stock price is 3,294% less volatile than the S&P 500.

Profitability

This table compares Emmaus Life Sciences and Curative Biotechnology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emmaus Life Sciences	N/A	N/A	N/A
Curative Biotechnology	N/A	N/A	N/A

Summary

Emmaus Life Sciences beats Curative Biotechnology on 4 of the 4 factors compared between the two stocks.

Curative Biotechnology vs. Pacific Health Care Organization Stock

Pacific Health Care Organization (OTCMKTS:PFHOD) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares Pacific Health Care Organization and Curative Biotechnology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pacific Health Care Organization	16.87%	14.47%	12.96%
Curative Biotechnology	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Pacific Health Care Organization and Curative Biotechnology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Health Care Organization	0	0	0	0	N/A
Curative Biotechnology	0	0	0	0	N/A

Earnings & Valuation

This table compares Pacific Health Care Organization and Curative Biotechnology's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Health Care Organization	$6.80 million	2.35	$1.36 million	N/A	N/A
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A

Pacific Health Care Organization has higher revenue and earnings than Curative Biotechnology.

Risk & Volatility

Pacific Health Care Organization has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, indicating that its stock price is 3,294% less volatile than the S&P 500.

Summary

Pacific Health Care Organization beats Curative Biotechnology on 5 of the 5 factors compared between the two stocks.